Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss how they developed the care models for their recent paper — Defining Comprehensive Models of Care for NAFLD.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join the Surfers to discuss their recent paper, “Defining Comprehensive Models of Care for NAFLD.” In this vitally important paper, the authors researched care models around the world to find the ones that work best, and then developed eight foundational recommendations for co-ordinated NAFLD care centers.
This week’s celebration podcast featured interviews including seven of our favorite Surfers. In this week’s conversations, we are publishing the interviews in full. Third up, Jörn Schattenberg and Ian Rowe
This week’s celebration podcast featured interviews including seven of our favorite Surfers. In this week’s conversations, we are publishing the interviews in full. Second up: Stephen Harrison and Naim Alkhouri
This week’s celebration podcast featured interviews including seven of our favorite Surfers. In this week’s conversations, we are publishing the interviews in full. First up: Donna Cryer.
Seven of our favorite Surfers join together to celebrate 20,000 Buzzsprout downloads and our one-year anniversary of moving to Buzzsprout.
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.
Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the challenges in communicating the importance of NASH to medical specialties other than hepatology and gastroenterology.
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. This conversation focuses on the unique challenges posed by the complexity of NASH and NAFLD and the current state of diagnostic testing. It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment.
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets. In this conversation, each panelist identifies one significant reason the NASH market will develop differently than statins did.
Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets.
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around care pathways and treatment roles as NASH becomes recognized as a multidisciplinary health challenge.
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around drug development.
Quentin Anstee, Louise Campbell, Stephen Harrison, Mazen Noureddin, Ian Rowe and Roger Green convene to review #ILC2021 and share key takeaways and insights. This conversation covers issues around diagnostics.
Key opinion leaders Quentin Anstee, Mazen Noureddin and Ian Rowe join Stephen, Louise and Roger to discuss the major lessons and dangling questions from #ILC2021.
Donna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021.
Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021.
Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021.
Jörn Schattenberg, Naim Alkhouri, Dr. Michelle Long of Boston University and Livia Alimena of the Global Liver Institute join Roger to review highlights of Day Two at ILC2021.
Incoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnostics Suneil Hosmane share their unique perspectives on Digital ILC 2021 with Roger Green.
Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green identify specific sessions and presentations they believe will bring the greatest enlightenment around tough challenges and unaddressed issues in Fatty Liver disease.
Stephen Harrison and Jörn Schattenberg discuss what the titles of Digital ILC 2021 presentations tell us about possible findings in drug development.
